INS-19 (Neupogen) and INS-20 (Neulasta) are included in the five or six biologics MRK says it will have in phase-3 by 2012, according to Reuters. This suggests MRK knew as early as last December that it would be acquiring INSM. <a href="http://www.reuters.com/article/marketsNews/idINN1243354920090212" target="_blank">http://www.reuters.com/article/marketsNews/idINN1243354920090212</a>